| Year |
Citation |
Score |
| 2021 |
Clerico A, Cardinale DM, Zaninotto M, Aspromonte N, Sandri MT, Passino C, Migliardi M, Perrone M, Fortunato A, Padoan A, Trenti T, Bernardini S, Sciacovelli L, Colivicchi F, Gabrielli D, et al. High-sensitivity cardiac troponin I and T methods for the early detection of myocardial injury in patients on chemotherapy. Clinical Chemistry and Laboratory Medicine. 59: 513-521. PMID 32441665 DOI: 10.1515/cclm-2020-0362 |
0.316 |
|
| 2020 |
Hurle R, Casale P, Saita A, Colombo P, Elefante GM, Lughezzani G, Fasulo V, Paciotti M, Domanico L, Bevilacqua G, Maffei D, Diana P, Frego N, Sandri MT, Maura F, et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. World Journal of Urology. 38: 2215-2220. PMID 31691083 DOI: 10.1007/s00345-019-03002-3 |
0.304 |
|
| 2019 |
Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, ... ... Sandri MT, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology. 134: 39-45. PMID 30771872 DOI: 10.1016/J.Critrevonc.2018.12.004 |
0.529 |
|
| 2018 |
Gioffre' S, Chiesa M, Alfieri I, Masson S, Latini R, Sandri MT, Cardinale D, Pompilio G, Colombo GI, D'Alessandra Y. P4763Circulating microRNAs as selective markers of anthracyclines-based therapies in breast cancer patients European Heart Journal. 39. DOI: 10.1093/EURHEARTJ/EHY563.P4763 |
0.393 |
|
| 2016 |
Aurilio G, Sandri MT, Pruneri G, Zorzino L, Botteri E, Munzone E, Adamoli L, Facchi G, Cullurà D, Verri E, Rocca MC, Zurrida S, Iacovelli R, Nolè F. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncology (London, England). 12: 2001-8. PMID 27255717 DOI: 10.2217/fon-2016-0081 |
0.428 |
|
| 2016 |
Salvatici M, Achilarre MT, Sandri MT, Boveri S, Vanna Z, Landoni F. Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence. Gynecologic Oncology. 142: 115-119. PMID 27117922 DOI: 10.1016/j.ygyno.2016.04.029 |
0.323 |
|
| 2016 |
Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Lascoiti AFd, ... ... Sandri M, et al. Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-08-08 |
0.508 |
|
| 2015 |
Balduzzi A, Bagnardi V, Sandri MT, Dellapasqua S, Cardillo A, Montagna E, Cancello G, Iorfida M, Ghisini R, Viale G, Intra M, Luini A, Goldhirsch A, Colleoni M. Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. Clinical Breast Cancer. 15: e257-62. PMID 26362840 DOI: 10.1016/j.clbc.2015.03.007 |
0.383 |
|
| 2015 |
Bissolati M, Sandri MT, Burtulo G, Zorzino L, Balzano G, Braga M. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 36: 991-6. PMID 25318603 DOI: 10.1007/s13277-014-2716-0 |
0.362 |
|
| 2014 |
Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, Andergassen U, Meier-Stiegen F, Czyz ZT, Alberter B, Treitschke S, Schamberger T, Sergio M, Bregola G, Doffini A, ... ... Sandri MT, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. Embo Molecular Medicine. 6: 1371-86. PMID 25358515 DOI: 10.15252/emmm.201404033 |
0.34 |
|
| 2014 |
Magni E, Botteri E, Ravenda PS, Cassatella MC, Bertani E, Chiappa A, Luca F, Zorzino L, Bianchi PP, Adamoli L, Sandri MT, Zampino MG. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. International Journal of Colorectal Disease. 29: 1053-9. PMID 25008360 DOI: 10.1007/s00384-014-1958-z |
0.383 |
|
| 2014 |
Ignatiadis M, Riethdorf S, Bidard FC, Vaucher I, Khazour M, Rothé F, Metallo J, Rouas G, Payne RE, Coombes R, Teufel I, Andergassen U, Apostolaki S, Politaki E, Mavroudis D, ... ... Sandri M, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Research : Bcr. 16: R43. PMID 24758318 DOI: 10.1186/bcr3647 |
0.421 |
|
| 2014 |
Salvatici M, Cardinale D, Botteri E, Bagnardi V, Mauro C, Cassatella MC, Lentati P, Bottari F, Zorzino L, Passerini R, Cipolla CM, Sandri MT. TnI-Ultra assay measurements in cancer patients: comparison with the conventional assay and clinical implication. Scandinavian Journal of Clinical and Laboratory Investigation. 74: 385-91. PMID 24693994 DOI: 10.3109/00365513.2014.898325 |
0.328 |
|
| 2014 |
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, ... ... Sandri MT, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet. Oncology. 15: 406-14. PMID 24636208 DOI: 10.1016/S1470-2045(14)70069-5 |
0.541 |
|
| 2014 |
Campiglio M, Sandri M, Sasso M, Bianchi F, Balsari A, Ménard S, Tagliabue E. Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: 1073-4. PMID 24558025 DOI: 10.1093/annonc/mdu058 |
0.364 |
|
| 2013 |
Yahalom G, Weiss D, Novikov I, Bevers TB, Radvanyi LG, Liu M, Piura B, Iacobelli S, Sandri MT, Cassano E, Allweis TM, Bitterman A, Engelman P, Vence LM, Rosenberg MM. An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomarkers in Cancer. 5: 71-80. PMID 24324350 DOI: 10.4137/BIC.S13236 |
0.314 |
|
| 2013 |
Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide. Breast Cancer Research and Treatment. 142: 569-78. PMID 24241787 DOI: 10.1007/s10549-013-2768-7 |
0.339 |
|
| 2013 |
Cassatella MC, Zorzino L, Sandri MT. Single circulating tumor cell profiling: a new perspective for targeted therapy? Future Oncology (London, England). 8: 1253-6. PMID 23130926 DOI: 10.2217/fon.12.119 |
0.384 |
|
| 2013 |
Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavrudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Antelo M, ... ... Sandri M, et al. Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd6-5 |
0.548 |
|
| 2012 |
Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clinical Breast Cancer. 12: 340-6. PMID 23040002 DOI: 10.1016/j.clbc.2012.07.001 |
0.418 |
|
| 2012 |
Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast (Edinburgh, Scotland). 21: 309-13. PMID 22341133 DOI: 10.1016/j.breast.2012.01.015 |
0.383 |
|
| 2012 |
Aurilio G, Sciandivasci A, Munzone E, Sandri MT, Zorzino L, Cassatella MC, Verri E, Rocca MC, Nolè F. Prognostic value of circulating tumor cells in primary and metastatic breast cancer. Expert Review of Anticancer Therapy. 12: 203-14. PMID 22316368 DOI: 10.1586/era.11.208 |
0.428 |
|
| 2012 |
Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 151-7. PMID 22162577 DOI: 10.1200/JCO.2011.35.2237 |
0.35 |
|
| 2012 |
Aurilio G, Munzone E, Botteri E, Pedroli S, Sandri M, Adamoli L, Zorzino L, Sciandivasci A, Esposito A, Nolè F. 41P Circulating Tumor Cells (CTCs) and Metronomic Oral Vinorelbine (OV) in Advanced Breast Cancer (ABC) Patients (PTS): Exploratory Prospective Analysis Annals of Oncology. 23: ii26. DOI: 10.1016/s0923-7534(19)65694-2 |
0.433 |
|
| 2011 |
Liu MC, Mego M, Nakamura S, Nole F, Pierga J, Toi M, Munzone E, Yagata H, Sandri MT, Bidard F, Wang H, Hayes DF, Cristofanilli M. Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10592. PMID 28021972 DOI: 10.1200/jco.2011.29.15_suppl.10592 |
0.376 |
|
| 2011 |
Fontana F, Bonizzi G, Medoro G, Zorzino L, Sergio M, Cassatella MC, Peruzzi E, Gianni S, Calanca A, Signorini G, Nole F, Giorgini G, Munzone E, Manaresi N, Sandri MT. Sequencing the chemokine receptor CXCR4 in individual circulating tumor cells (CTCs) of patients with breast cancer (BrCa). Journal of Clinical Oncology. 29: e21134-e21134. DOI: 10.1200/JCO.2011.29.15_SUPPL.E21134 |
0.399 |
|
| 2010 |
Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clinical Breast Cancer. 10: 392-7. PMID 20920984 DOI: 10.3816/CBC.2010.n.052 |
0.314 |
|
| 2010 |
Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 3910-6. PMID 20679614 DOI: 10.1200/JCO.2009.27.3615 |
0.328 |
|
| 2010 |
Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, Botteri E, Rotmensz N, Adamoli L, Nolè F. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Annals of Surgical Oncology. 17: 1539-45. PMID 20135356 DOI: 10.1245/s10434-010-0918-2 |
0.455 |
|
| 2010 |
Alunni-Fabbroni M, Sandri MT. Circulating tumour cells in clinical practice: Methods of detection and possible characterization. Methods (San Diego, Calif.). 50: 289-97. PMID 20116432 DOI: 10.1016/j.ymeth.2010.01.027 |
0.323 |
|
| 2010 |
Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Research and Treatment. 122: 211-7. PMID 19967556 DOI: 10.1007/s10549-009-0668-7 |
0.484 |
|
| 2009 |
Rocca A, Cancello G, Bagnardi V, Sandri MT, Torrisi R, Zorzino L, Viale G, Pietri E, Veronesi P, Dellapasqua S, Ferrucci F, Luini A, Johansson H, Ghisini R, Goldhirsch A, et al. Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer. Anticancer Research. 29: 5111-9. PMID 20044624 |
0.391 |
|
| 2009 |
Contino G, Bertani E, Zampino G, Zorzino L, Magni E, Andreoni B, Sandri M, Chiappa A. P10 Detection of circulating tumor cells (CTCs) in Stage cT3–4orN+ rectal cancer patients (pts) undergoing combined neoadjuvant therapy plus curative surgery. Preliminary data European Journal of Cancer Supplements. 7: 35. DOI: 10.1016/S1359-6349(09)72226-8 |
0.32 |
|
| 2008 |
Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A. Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Research and Treatment. 108: 57-67. PMID 17468953 DOI: 10.1007/s10549-007-9577-9 |
0.317 |
|
| 2008 |
Munzone E, Nolé F, Zorzino L, Medici M, Minchella I, Cassatella MC, Casadio C, Picozzi M, Adamoli L, Goldhirsch A, Sandri M. Acquisition of HER2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy Journal of Clinical Oncology. 26: 11017-11017. DOI: 10.1200/JCO.2008.26.15_SUPPL.11017 |
0.421 |
|
| 2007 |
Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 19: 891-7. PMID 18056915 DOI: 10.1093/ANNONC/MDM558 |
0.464 |
|
| 2007 |
Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer. 110: 509-17. PMID 17559147 DOI: 10.1002/cncr.22825 |
0.444 |
|
| 2005 |
Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 17: 232-8. PMID 16322118 DOI: 10.1093/ANNONC/MDJ066 |
0.347 |
|
| 2005 |
Intra M, Gentilini O, Brenelli F, Chagas EM, Veronesi U, Sandri MT. Breast cancer among HIV-infected patients: the experience of the European Institute of Oncology. Journal of Surgical Oncology. 91: 141-2. PMID 16028288 DOI: 10.1002/JSO.20315 |
0.303 |
|
| 2004 |
Sandri MT, Johansson H, Colleoni M, Zorzino L, Passerini R, Orlando L, Viale G. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma. Anticancer Research. 24: 1261-6. PMID 15154657 |
0.406 |
|
| 2004 |
Colleoni M, Curigliano G, Minchella I, Peruzzotti G, Nolè F, Mazzarol G, Renne G, Orlando L, Rocca A, Veronesi P, Intra M, Viale G, Sandri MT, Severi G, Goldhirsch A. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 14: 1477-83. PMID 14504046 DOI: 10.1093/ANNONC/MDG411 |
0.347 |
|
| 2003 |
Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrisi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. Journal of the National Cancer Institute. 95: 779-90. PMID 12783932 DOI: 10.1093/JNCI/95.11.779 |
0.32 |
|
| Show low-probability matches. |